Empor.top - The Stories of Top Companies

Recursion Pharmaceuticals faces scrutiny over high losses, revenue concentration, and unproven AI drug platform despite promising REC-4881 data.

1h 7m Listen to the original Episode page
BiotechnologyAI Drug DiscoveryClinical TrialsFinancial AnalysisRisk ManagementValuationCorporate GovernancePharma Partnerships

Summary

Speakers analyze Recursion Pharmaceuticals' Q2 2026 earnings, highlighting a net loss of $645 million against $74 million in revenue driven by two major partners. The episode details the company's acquisition of Exscientia for $688 million and subsequent integration challenges, including material weaknesses in internal controls. Clinical data for REC-4881 showed a 43% reduction in polyp burden, but speakers caution that this single signal does not validate the broader AI platform or guarantee commercial success. The discussion covers the company's cash burn rate, dilution from equity financing, and the high concentration risk associated with its customer base. Ultimately, the speakers argue that Recursion's valuation relies on future partner validation and clinical proof rather than current financial performance.

Key takeaways

  1. 1
    REC-4881 demonstrated a median 43% reduction in polyp burden after three months of treatment in patients with familial adenomatous polyposis, a rare inherited disease.

    Unidentified speaker (speaker_0) · 1:20

Episode sections

  1. 0:00 – 4:52

    The Drug Discovery Machine Meets Its Hardest Test

    Introduction to Recursion's Q2 2026 earnings, highlighting the contrast between promising clinical data for REC-4881 and steep financial losses.

  2. 4:52 – 9:42

    A Cell-Painting Lab Becomes a Public Company

    Overview of Recursion's origin, automated cell-painting technology, and its 2021 IPO promise to use machine learning for drug discovery.

  3. 9:42 – 16:13

    The Map, the Molecule and the Pharma Partner

    Explanation of revenue models tied to partnerships with Roche/Genentech and Sanofi, noting high concentration risk and lumpy payments.

  4. 16:13 – 21:54

    The $688 Million Bet on Exscientia

    Details of the Exscientia acquisition, including the premium paid, integration challenges, and auditor-identified control weaknesses.

  5. 21:54 – 28:12

    The Pipeline Gets Smaller as the Company Tries to Get More From Each Dollar

    Discussion of cost-cutting measures, including program cuts and headcount reductions, and the company's path to break-even.

  6. 28:12 – 31:58

    REC-4881 Gives the Platform Its First Patient-Level Test

    Analysis of REC-4881 clinical data, emphasizing the promise of polyp reduction while noting unproven tolerability and long-term efficacy.

  7. 31:58 – 33:00

    Clinical Validation and Pipeline Options

    Distinction between a platform producing a hypothesis and a proven commercial model, with other pipeline programs treated as options.

  8. 33:00 – 34:42

    Efficiency Claims vs. Commercial Reality

    Critique of efficiency claims, arguing that faster routes to failure only save money if they lead to successful medicines.

  9. 34:42 – 40:28

    Competitive Landscape and Moat Analysis

    Analysis of Recursion's competitive position using Porter's Five Forces, noting a lack of proven switching costs or network effects.

  10. 40:28 – 46:09

    Leadership Transition and Accountability

    Overview of CEO Najat Khan's background and her responsibility for integrating Exscientia and remediating control weaknesses.

  11. 46:09 – 52:26

    Cash Burn, Dilution, and Runway

    Discussion of substantial cash burn, equity dilution from stock-based compensation, and the company's financing history.

  12. 52:26 – 54:15

    Valuation and Market Expectations

    Analysis of the stock's premium valuation, implying expectations of future product success rather than current revenue justification.

  13. 54:15 – 59:37

    Bull and Bear Case Summary

    Summary of the bull case (partner validation, REC-4881 signal) versus the bear case (losses, concentration, dilution).

  14. 59:37 – 1:06:50

    Investment Lessons and Decision Points

    Five lessons for investors, emphasizing data as the beginning, not the end, and patient approval as the true proof.

Claims worth verifying

Najat Khan opened Recursion's second quarter earnings call on August 5th, 2026, presenting evidence of a partner advancing a target and clinical data for REC-4881.

Unidentified speaker (speaker_0) ·0:32

How to verify: Recursion Pharmaceuticals Q2 2026 Earnings Call transcript or press release, available on SEC EDGAR or Recursion investor relations page. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-4881 was associated with a median 43% reduction in polyp burden after three months of treatment in patients with familial adenomatous polyposis.

Unidentified speaker (UNKNOWN) ·1:20

How to verify: Recursion Pharmaceuticals Q2 2026 Earnings Call transcript or clinical trial results database (e.g., ClinicalTrials.gov) for the Tupelo study. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

In 2025, Recursion booked about $74 million of revenue and reported a net loss of roughly $645 million.

Unidentified speaker (UNKNOWN) ·2:24

How to verify: Recursion Pharmaceuticals 2026 Annual Report (Form 10-K) filed with SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

In the first half of 2026, revenue fell about 60% from the same period a year earlier.

Unidentified speaker (UNKNOWN) ·2:42

How to verify: Recursion Pharmaceuticals Q2 2026 Earnings Report or Form 10-Q filed with SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion held about $557 million of cash, cash equivalents, and restricted cash at the end of June 2026.

Unidentified speaker (speaker_0) ·3:02

How to verify: Recursion Pharmaceuticals Q2 2026 Form 10-Q filed with SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion guided to roughly $375 million of cash operating expenses for the year 2026.

Unidentified speaker (speaker_0) ·3:02

How to verify: Recursion Pharmaceuticals Q2 2026 Earnings Call transcript or press release. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

On October 29th, 2026, Recursion's share price was about $4.34, valuing the company at roughly $2.3 billion.

Unidentified speaker (speaker_0) ·3:22

How to verify: Historical stock price data from financial data providers (e.g., Bloomberg, Yahoo Finance) and public float calculations. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Recursion acquired Exscientia on August 8th, 2024, for an implied value of about $688 million.

Unidentified speaker (speaker_0) ·16:13

How to verify: Recursion Pharmaceuticals press release announcing the acquisition of Exscientia, available on SEC EDGAR or Recursion investor relations. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Exscientia shareholders received a premium of about 25% to the three-month average share price ratio.

Unidentified speaker (UNKNOWN) ·17:02

How to verify: Recursion Pharmaceuticals proxy statement or merger agreement details filed with SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion spent about $475 million on research and development in 2025.

Unidentified speaker (speaker_0) ·13:44

How to verify: Recursion Pharmaceuticals 2025 Annual Report (Form 10-K) filed with SEC EDGAR. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-4881 has shown a promising signal in patients with FAP (Familial Adenomatous Polyposis).

Unidentified speaker (UNKNOWN) ·31:58

How to verify: Check Recursion Pharmaceuticals' Q2 2026 earnings report or press releases for REC-4881 clinical data updates. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-617 is a CDK7 inhibitor for advanced solid tumors that came from Exscientia and has reported early data.

Unidentified speaker (UNKNOWN) ·32:10

How to verify: Review Recursion Pharmaceuticals' pipeline disclosures in SEC filings (e.g., 10-K or 10-Q) or press releases regarding Exscientia assets. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion's R&D spending dwarfed its revenue in 2025.

Unidentified speaker (speaker_0) ·33:28

How to verify: Compare R&D expense and total revenue figures in Recursion Pharmaceuticals' 2025 Form 10-K filed with the SEC. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Najat Khan became CEO on January 1, 2026.

Unidentified speaker (speaker_0) ·40:48

How to verify: Check Recursion Pharmaceuticals' proxy statement (DEF 14A) or press release announcing the CEO transition. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Chris Gibson moved to chair the board after Khan became CEO.

Unidentified speaker (speaker_0) ·40:48

How to verify: Review Recursion Pharmaceuticals' proxy statement or press release regarding board composition changes. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Vanguard holds about 9.0% of Class A shares, BlackRock about 7.2%, and ARK Invest (Kathy Woods) about 7.1% as of April 2026.

Unidentified speaker (UNKNOWN) ·43:56

How to verify: Review 13F filings for Vanguard, BlackRock, and ARK Invest for the Q1 2026 reporting period. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion's cumulative net losses from 2019 through 2025 were about $2.0 billion, while cash burned was about $1.4 billion.

Unidentified speaker (UNKNOWN) ·46:51

How to verify: Sum the net loss and operating cash flow from Recursion Pharmaceuticals' quarterly 10-Q filings from 2026 to 2026. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion raised about $492 million net in 2025 through an at-the-market program by selling about 99.9 million shares.

Unidentified speaker (speaker_0) ·48:59

How to verify: Check Recursion Pharmaceuticals' Form 8-K filings for the 2025 ATM offering and the related prospectus supplement. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-4881 produced a patient-level signal in a small, uncontrolled study.

Unidentified speaker (speaker_0) ·55:55

How to verify: Review Recursion Pharmaceuticals' Q2 2026 earnings report or clinical data presentations for details on the REC-4881 study design and results. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-4881 has shown early polyp reductions in patients.

Unidentified speaker (speaker_0) ·1:03:03

How to verify: Check Recursion Pharmaceuticals' SEC filings (e.g., 10-K or 10-Q) or press releases for clinical trial results of REC-4881, specifically looking for polyp reduction data. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion has partnerships with Roche, Genentec, and Sanofi.

Unidentified speaker (UNKNOWN) ·1:03:34

How to verify: Search Recursion Pharmaceuticals' investor relations website or SEC filings (e.g., 8-K or 10-K) for partnership agreements with Roche, Genentec, and Sanofi. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion estimates its cash will last into early 2028.

Unidentified speaker (UNKNOWN) ·1:04:07

How to verify: Review Recursion Pharmaceuticals' latest quarterly earnings report or 10-K filing for cash runway guidance and cash balance projections. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Recursion has Essentia-related control weaknesses.

Unidentified speaker (speaker_0) ·1:04:30

How to verify: Check Recursion Pharmaceuticals' most recent 10-K or 10-Q filing for the 'Internal Control over Financial Reporting' section, specifically looking for material weaknesses related to Essentia. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

REC-4881 produced an early patient-level signal after more than a decade and billions of dollars of shareholder money.

Unidentified speaker (speaker_0) ·1:05:35

How to verify: Verify Recursion Pharmaceuticals' total cash raised from inception via SEC filings (e.g., Statement of Cash Flows) and check clinical trial data for REC-4881 patient-level results. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Review Recursion's 10-K and 10-Q filings for 2025 and 2026 to verify the $645 million net loss and $74 million revenue figures.
  • Examine the Exscientia acquisition agreement and subsequent auditor reports for details on material weaknesses in internal controls.
  • Analyze the REC-4881 clinical trial data (NCT number required) for patient sample size, side effect profiles, and long-term efficacy metrics.
  • Check the company's cash runway projections against quarterly cash burn rates and potential dilution from at-the-market offerings.
  • Identify the specific revenue recognition policies for partnership contracts to understand how cost estimates impact reported revenue.
  • Verify the concentration of revenue by reviewing the customer disclosure in the latest 10-K to confirm the two-customer dependency.
  • Assess the competitive landscape by comparing Recursion's proprietary data moat against competitors like Schrödinger and Insilico Medicine.
  • Monitor FDA communications regarding REC-4881 for any safety signals or requests for additional data that could impact development timelines.
Full transcriptexpand
0:00
Unidentified speaker (speaker_0): This podcast is brought to you by mPor.top, the stories of top companies. Disclaimer: this AI-generated content is for informational purposes only and should not be considered as investment advice.
0:12
Unidentified speaker (UNKNOWN): If
0:13
Unidentified speaker (speaker_0): you like our podcasts, please subscribe on Apple Podcasts, Spotify, or your favorite podcast player, and don't forget to follow us on X at mport.top. MPOR.top. Find thousands of stories of top companies on our website, mPor.org. mPor.top. MPOR.top is brought to you by heyfin.co. Finn is a
0:32
Unidentified speaker (speaker_0): personalized junior AI research assistant for equity portfolio managers. Check it out at heyfin.co. Recursion Pharmaceuticals. Can AI turn biology into medicines? On August 5th, 2026, Najat Khan opened Recursion's second quarter earnings call with something the company had spent most of a
0:52
Unidentified speaker (speaker_0): decade promising and only rarely delivering. Evidence that pointed outside its own walls. The first piece came from a partner.
1:01
Unidentified speaker (UNKNOWN): A
1:01
Unidentified speaker (speaker_0): neuroscience target that Recursion had surfaced while building maps of human cell biology for Roche and its Genentech unit had been moved into a joint early discovery program, meaning a large pharmaceutical company had looked at the work and decided to spend its own scientists' time chasing
1:17
Unidentified speaker (UNKNOWN): it. The
1:18
Unidentified speaker (speaker_0): second piece came from patients.
1:20
Unidentified speaker (UNKNOWN): In
1:20
Unidentified speaker (speaker_0): a rare inherited disease called familial adenomatous polyposis, a recursion drug candidate named REC four eight eight one had been associated with a median forty-three percent reduction in polyp burden after three months of treatment. Those are not small things for a company like this.
1:37
Unidentified speaker (UNKNOWN): For
1:38
Unidentified speaker (speaker_0): years, the case for recursion rested on a picture of the future. Robots running millions of experiments on human cells, cameras photographing every one of them, and machine learning models finding patterns that no human biologist could see.
1:52
Unidentified speaker (UNKNOWN): It
1:52
Unidentified speaker (speaker_0): is a beautiful idea.
1:54
Unidentified speaker (UNKNOWN): The
1:54
Unidentified speaker (speaker_0): problem with beautiful ideas in drug discovery is that the industry is a graveyard of
1:59
Unidentified speaker (UNKNOWN): them.
2:00
Unidentified speaker (speaker_0): Medicines are judged in people, by records. regulators, over years, and most candidates that enter human trials never reach the market. A platform that generates insight is not the same as a company that generates medicines, and a company that generates medicines is not the same as one that generates cash. That gap is the
2:20
Unidentified speaker (speaker_0): subject of this story,
2:21
Unidentified speaker (UNKNOWN): and
2:22
Unidentified speaker (speaker_0): the scale of it is easy to state.
2:24
Unidentified speaker (UNKNOWN): In
2:24
Unidentified speaker (speaker_0): 2025, Recursion booked about seventy. $74 million of revenue, nearly all of it from research partnerships, and reported a net loss of roughly $645 million.
2:35
Unidentified speaker (UNKNOWN): For
2:35
Unidentified speaker (speaker_0): every dollar of revenue it recognized, it lost almost nine. Then the revenue line went the wrong way.
2:42
Unidentified speaker (UNKNOWN): In
2:42
Unidentified speaker (speaker_0): the first half of 2026, revenue fell about 60% from the same period a year earlier, as partner work shifted between project phases. On paper, the company looked smaller and still deeply unprofitable at the very moment it said its science was getting more convincing. Against that, the company held about $557 million
3:02
Unidentified speaker (speaker_0): of cash, cash equivalents, and restricted cash at the end of June 2026, and management guided to roughly $375 seventy five million dollars of cash operating expenses for the year. That is the countdown clock running. beneath everything else. The market, meanwhile, was paying for the future rather than the present. At about four dollars thirty four cents
3:22
Unidentified speaker (speaker_0): a share on October twenty ninth, twenty twenty six, recursion was worth roughly two point three billion dollars, around forty two point five times its trailing twelve months of revenue. Investors were not buying a royalty stream or a product franchise. They were buying a probability. Three tests run through the rest of this story. The first
3:42
Unidentified speaker (speaker_0): is whether the platform produces repeatable value, not one lucky hit, but a pattern of partner programs that advance and drug candidates that work. The second is whether the 2024 acquisition of the British AI drug designer Accenture and the cost cuts and pipeline pruning that followed it made the business stronger or merely larger and then
4:01
Unidentified speaker (speaker_0): smaller again.
4:03
Unidentified speaker (UNKNOWN): The
4:03
Unidentified speaker (speaker_0): third is whether recursion can buy enough proof before the cash runs low, without asking shareholders to fund the experiment over and over through new stock.
4:12
Unidentified speaker (UNKNOWN): The
4:12
Unidentified speaker (speaker_0): honest verdict at the start is a narrow one. The August call offered the most concrete evidence recursion has produced: a partner moving a target forward and a clinical signal in the disease with no approved therapy that modifies its course. Neither isn't is approved. an drug, a royalty, or a durable business model. The platform has begun to produce
4:32
Unidentified speaker (speaker_0): useful biology and promising clinical data. Whether those early signs repeat and whether they repeat cheaply enough is the question that the next two years will answer. To see why that question is so hard, the story has to start in a lab in Salt Lake City with a graduate student who thought biology had a data. problem. Picture
4:52
Unidentified speaker (speaker_0): a laboratory where almost no one holds a pipette. In Recursion's Salt Lake City facility, robotic arms move plates of human cells between incubators, liquid handlers, and microscopes. Each plate holds hundreds of tiny wells, and each well holds cells that have been disturbed in some deliberate way. A gene switched
5:12
Unidentified speaker (speaker_0): off, a chemical compound added, a protein. that signals inflammation dripped in. Then the cells are stained with fluorescent dyes that light up their nucleus, their mitochondria, their skeleton, and other structures, and photographed. The result is a picture of what that disturbance did to the cell's shape and organization.
5:31
Unidentified speaker (speaker_0): Multiply that by millions of wells, and the lab becomes a factory for images of biology under stress.
5:38
Unidentified speaker (UNKNOWN): The
5:38
Unidentified speaker (speaker_0): company traced its origin to 2013 and to Chris Gibson, then an MD PhD student at the University of Utah, who co-founded Recursion with colleagues from the lab of his mentor, Dean Lye. Gibson's insight was not that computers would replace biologists, it was that drug discovery spends most of its money on hypotheses that turn out
5:58
Unidentified speaker (speaker_0): to be wrong, and that the industry tests those hypotheses slowly, one disease. and one target at a time.
6:05
Unidentified speaker (UNKNOWN): If
6:05
Unidentified speaker (speaker_0): you could run experiments at enormous scale and let software compare them, you might see that a drug which reverses one cellular defect also reverses another, or that two genes that look unrelated produce the same visual signature when they break. Biology is too complex to reason through from first principles. Perhaps it could be
6:25
Unidentified speaker (speaker_0): searched.
6:25
Unidentified speaker (UNKNOWN): The
6:26
Unidentified speaker (speaker_0): method has a plain English shape that the company calls a loop. Perturb the cells, photograph the result, train models to recognize which pictures resemble each other and which differ from a healthy baseline. Use those patterns to choose the next experiment, then repeat, and each cycle should make the next guess better. Think of it as
6:45
Unidentified speaker (speaker_0): learning a language by reading millions of sentences rather than memorizing a grammar book. The models never understand a disease the way a physician does, but they can notice that two sentences mean the same thing even when the words are different.
7:01
Unidentified speaker (UNKNOWN): By
7:01
Unidentified speaker (speaker_0): the time recursion filed to go public in March 2021, it described a dataset of nearly eight petabytes of biological and chemical data, a scale few young biotech companies could match.
7:13
Unidentified speaker (UNKNOWN): It's
7:14
Unidentified speaker (speaker_0): pitch to investigate. investors was that this data and the automated lab around it let it explore many disease programs in parallel, kill weak ideas earlier, and pick better ones at the discovery stage, where decisions are cheapest to change. Recursion listed on NASDAQ in April 2021 under the ticker RXRX, in a
7:33
Unidentified speaker (speaker_0): market eager to fund anything that combined biotechnology with artificial intelligence. What investors were actually buying deserves to be said plainly. In 2019, Recursion's revenue was roughly $1 million, and in 2020, about $3 million. The company was not a software business with predictable subscriptions, nor a
7:53
Unidentified speaker (speaker_0): biotech with a late-stage drug. It was a research platform with an early pipeline, financed by investors who believed the platform would compound into millions. many medicines.
8:04
Unidentified speaker (UNKNOWN): By
8:04
Unidentified speaker (speaker_0): twenty twenty five, revenue had grown from that small base, an increase that looks spectacular as a growth rate and modest as a business. It still came almost entirely from partnership contracts. There is a common narrative that data scale is itself the moat, that whoever owns the most petabytes wins. The record does not support
8:24
Unidentified speaker (speaker_0): that conclusion yet.
8:25
Unidentified speaker (UNKNOWN): Scale
8:26
Unidentified speaker (speaker_0): is a real asset. Recursion built physical infrastructure, collected proprietary experimental data under controlled conditions, and, with help from NVIDIA, built one of the larger supercomputers in the biopharmaceutical industry. But nearly eight petabytes of images is an input, like a library full of books. It becomes an
8:45
Unidentified speaker (speaker_0): advantage only if it leads to decisions that other teams cannot make as well or as cheaply.
8:51
Unidentified speaker (speaker_0): The S1's promise was explicitly about better and faster discovery stage decisions. That promise is testable, and the rest of the story tests
9:00
Unidentified speaker (UNKNOWN): it. The
9:01
Unidentified speaker (speaker_0): founding period also set a cultural pattern that still shapes the company. Recursion presented itself less as a biotech and more as a technology company that happened to work on medicines, with talk of maps, operating systems, and industrial. industrialized discovery.
9:16
Unidentified speaker (UNKNOWN): That
9:16
Unidentified speaker (speaker_0): language helped it raise money. It also created a standard that would later bite. If the machine is so productive, investors would eventually ask, where are the medicines and who is paying for
9:27
Unidentified speaker (UNKNOWN): them? The
9:28
Unidentified speaker (speaker_0): first answer Recursion gave was the big pharmaceutical partner, and that is where the story turns next. Somewhere inside Roche's research organization, a team of neuroscience. neuroscientists received a package from Salt Lake City.
9:42
Unidentified speaker (UNKNOWN): It
9:42
Unidentified speaker (speaker_0): was not a drug, it was a map. A data set in which recursion had knocked out genes across human neural cell types, photographed the consequences, and used its models to cluster which genes and pathways behaved alike. Roche's scientists had to decide whether the map was good enough to accept, because acceptance carried.
10:03
Unidentified speaker (speaker_0): a price. Under the collaboration, each accepted neuroscience map triggered a fee of thirty million dollars. Over time, Roche and Genentech accepted multiple such maps, and by the August 2026 call, one target drawn from that work had moved into a joint early discovery program.
10:21
Unidentified speaker (UNKNOWN): That
10:21
Unidentified speaker (speaker_0): is what recursion's partnerships actually sell, and it is worth understanding the contract mechanism. mechanics because they explain almost everything about the revenue line. Roche and Genentech signed on in December 2021 with a $150 million upfront payment, along with a possibility of map fees, program milestones, and royalties
10:41
Unidentified speaker (speaker_0): on any medicines that eventually reach the market. Sanafi's relationship arrived through Acentia, which had signed a deal with a $100 million upfront payment, milestone payments,
10:50
Unidentified speaker (UNKNOWN): and the colour.
10:51
Unidentified speaker (speaker_0): potential royalties. None of this resembles a subscription. There is no monthly seat license and no minimum recurring commitment disclosed in the filings. Payments arrive as lumps when work is delivered, accepted, or advanced.
11:05
Unidentified speaker (UNKNOWN): The
11:05
Unidentified speaker (speaker_0): accounting turns those lumps into something smoother, but still uneven. Even. When a partner pays an upfront fee, recursion does not book it as revenue all at once. It records the cash as unearned revenue and then recognizes it gradually as it performs the work, measured by costs incurred against the total costs it expects to spend.
11:24
Unidentified speaker (UNKNOWN): That
11:24
Unidentified speaker (speaker_0): method depends on estimates, so when management changes its view of how much work remains, revenue moves.
11:30
Unidentified speaker (UNKNOWN): In
11:31
Unidentified speaker (speaker_0): the fourth quarter of 2025, an updated cost estimate added about twelve point four million dollars to revenue, which helps explain why that's that single quarter showed roughly thirty five million dollars of revenue, while the quarters on either side showed single digit millions. Investors who saw first half twenty twenty six revenue fall about sixty percent were partly
11:50
Unidentified speaker (speaker_0): watching the mirror image of that pattern as work shifted between phases and the large recognition events of twenty twenty five did not recur. The partners matter in two ways at once. They are customers and they are digital. judges. A pharma company that pays $30 million for a map is voting with its budget that the map has value. Yet that dual
12:10
Unidentified speaker (speaker_0): role also creates the most obvious concentration risk in the business. In 2025, two customers each exceeded 10% of revenue and together represented substantially all of recursion's Curzon's operating revenue. The concentration note does not name them, though the revenue discussion makes the cast. fairly clear. Sonofi revenue rose because 2025
12:30
Unidentified speaker (speaker_0): included a full year of the acquired Acentia contract, while Roche revenue fell with the mix and timing of performance obligations.
12:38
Unidentified speaker (UNKNOWN): A
12:38
Unidentified speaker (speaker_0): company whose reported sales depend on two counterparties has a revenue line that tells you mostly about the pacing of two research programs.
12:45
Unidentified speaker (UNKNOWN): The
12:45
Unidentified speaker (speaker_0): roster has also been thinner than the list of famous partner names suggests. In twenty 2024, twenty four, only one customer crossed the 10% threshold. In 2023, two did. Bayer, an early collaborator, redirected its work with recursion from fibrosis to oncology in 2023, a change of scope rather than a lost customer, but a reminder that partners
13:05
Unidentified speaker (speaker_0): reshaped these deals to suit their own priorities. No major customer Your has defaulted nor or gone bankrupt, and the filings show no unusual credit terms or overdue balances. The risk is not that partners fail to pay, it is that they decide on their own timetable how much more to buy. Management likes to point to a larger number.
13:24
Unidentified speaker (UNKNOWN): By
13:24
Unidentified speaker (speaker_0): early 2026, it said cumulative cash inflows from partnerships had exceeded $500 million across upfront payments and milestones. That is a real figure and a meaningful one. Half a billion dollars of non-delivery. non-dilutive money is money shareholders did not have to provide. But set it beside the
13:44
Unidentified speaker (speaker_0): cost of the enterprise. Recursion spent about $475 million on research and development in 2025 alone. Several years of partner cash added together roughly equal a single year of RD. Partnerships have helped fund the company. They have not come close to
14:02
Unidentified speaker (UNKNOWN): the market.
14:03
Unidentified speaker (speaker_0): funding
14:03
Unidentified speaker (UNKNOWN): it. The
14:04
Unidentified speaker (speaker_0): Genentech step deserves its proper weight. Moving a target into a joint discovery program is evidence that a sophisticated buyer found the biology credible enough to invest more. It is also a long way from a medicine.
14:18
Unidentified speaker (UNKNOWN): A
14:18
Unidentified speaker (speaker_0): discovery program must still find a molecule, show that it works in animals, pass past toxicology, enter human trials, and then survive them.
14:26
Unidentified speaker (UNKNOWN): Each
14:26
Unidentified speaker (speaker_0): of those gates has historically eliminated most candidates across the industry. An accepted map is a vote of interest. A royalty check is a vote of success. Recursion has many of the former and none of the latter yet.
14:40
Unidentified speaker (UNKNOWN): On
14:40
Unidentified speaker (speaker_0): the second quarter call, an analyst pressed on the question that now hangs over every AI drug discovery company. As generative AI tools spread and large pharma builds
15:09
Unidentified speaker (UNKNOWN): That
15:09
Unidentified speaker (speaker_0): is the right answer to test, because it is falsifiable. If the integrated workflow is the edge, it should show up as partner programs advancing at a better rate and internal programs reaching clinical proof faster or more cheaply than peers. A model can be copied or licensed. A decade of physical experiments
15:29
Unidentified speaker (speaker_0): and the habits of using them are harder to replicate.
15:33
Unidentified speaker (UNKNOWN): The
15:33
Unidentified speaker (speaker_0): partnership record, weighed as a whole, supports a narrower claim than the one recursion made at its IP. IPO. Partners have paid real money, accepted real work, and in the Genentech case, carried a target forward. That establishes the platform as a credible research supplier to large pharma. It does not yet establish repeatable
15:53
Unidentified speaker (speaker_0): revenue, because the base is two customers deep and moves with acceptance events, and it does not establish that the work leads to medicines.
16:01
Unidentified speaker (UNKNOWN): And
16:01
Unidentified speaker (speaker_0): it leaves an awkward question. hanging. If partners were paying handsomely for discoveries, why did Recursion need to go out and buy another platform?
16:09
Unidentified speaker (UNKNOWN): In
16:09
Unidentified speaker (speaker_0): August 2024, it did exactly that.
16:12
Unidentified speaker (UNKNOWN): On
16:13
Unidentified speaker (speaker_0): August eighth, twenty twenty four, Recursion announced that it would combine with Exchantia, an Oxford-based company that had been one of the earliest public champions of AI design designed drugs.
16:24
Unidentified speaker (UNKNOWN): The
16:24
Unidentified speaker (speaker_0): pitch was a story of two halves fitting together.
16:27
Unidentified speaker (speaker_0): Recursion had built a factory for biological insight, very good at suggesting which targets and pathways mattered. Excentia had built a precision chemistry engine, using computational design and automated synthesis to create molecules with fewer rounds of trial and error. Put them together, the companies argued, and you would have something close to
16:47
Unidentified speaker (speaker_0): an end-to-end end to end machine. Biology in at one end, drug candidates out the other.
16:53
Unidentified speaker (UNKNOWN): The
16:53
Unidentified speaker (speaker_0): deal was paid entirely in stock. Exchantia shareholders received recursion shares, and Reuters put the implied value at about six hundred eighty eight million dollars.
17:02
Unidentified speaker (UNKNOWN): The
17:02
Unidentified speaker (speaker_0): exchange ratio gave Exchantia holders a premium of about twenty five percent to the three month average share price ratio between the two companies, and about thirty 32% two percent to the six six-month month average.
17:12
Unidentified speaker (UNKNOWN): When
17:12
Unidentified speaker (speaker_0): the deal closed on november twentieth, 20, twenty twenty 2024, four. Recursion's prior shareholders held roughly three quarters of the combined company, and Excentia's holders the rest.
17:21
Unidentified speaker (UNKNOWN): The
17:22
Unidentified speaker (speaker_0): companies also said they expected meaningful annual cost synergies and a combined cash position that would fund operations for several years.
17:29
Unidentified speaker (UNKNOWN): The
17:30
Unidentified speaker (speaker_0): all stock structure is the first thing an investor should understand. Stand. It meant Recursion did not have to spend its cash, which it needed for research, and it meant Excentia's investors. swapped one bet on AI drug discovery for another. But stock is not free money. About a hundred and two million new recursion shares went to Excentia holders, so every existing
17:49
Unidentified speaker (speaker_0): recursion shareholder now owned a smaller slice of a bigger company. Whether that was a good trade depends on whether the slice became more valuable than the whole had been before, and that comes down to what Excentia actually brought.
18:01
Unidentified speaker (UNKNOWN): There
18:01
Unidentified speaker (speaker_0): was context that made the deal look different to different people. Exitia had a troubled 2024 before the merger. Its board had removed founder and chief executive Andrew Hopkins earlier in the year after an investigation into his conduct, and the company had been narrowing its pipeline. Its share price had fallen far from
18:21
Unidentified speaker (speaker_0): its post postlisting listing peak.
18:23
Unidentified speaker (UNKNOWN): A
18:23
Unidentified speaker (speaker_0): buyer could see a discounted asset with real chemistry. capability, a Sonofi collaboration, and several clinical programs.
18:31
Unidentified speaker (UNKNOWN): A
18:31
Unidentified speaker (speaker_0): skeptic could see an AI pioneer whose own record had not yet produced a breakthrough, acquired at a premium by another AI pioneer in the same position. Benchmarking the price precisely is harder than it sounds. The premiums of about 25% and 32% are observable, and they sit
18:50
Unidentified speaker (UNKNOWN): down.
18:50
Unidentified speaker (speaker_0): within the range of ordinary public company takeover premiums. What does not exist in the public record is a clean set of comparable transactions, AI drug discovery companies acquired at known multiples of anything measurable, against which to call the price high or low. Exitiya had no product revenue and lumpy partnership income, just
19:10
Unidentified speaker (speaker_0): like recursion. So the defensible conclusion is narrower. The premium was not extraordinary, but the deal was a demanding bet, because its value depended entirely on things that had not yet been proven.
19:23
Unidentified speaker (UNKNOWN): The
19:23
Unidentified speaker (speaker_0): numbers that arrived inside the combined company show why. In twenty twenty five, the first full year of ownership, the acquired exitia business contributed about thirty five point three million dollars of recursion's revenue, most of it from the Sanofi relationship, and about one hundred fifty eight point four million dollars of operating loss. Those figures do not
19:43
Unidentified speaker (speaker_0): capture the deal's full value because programs and capabilities that migrate into the combined pipeline do not show up neatly by legal entity, but they make a crucial point. More pipeline came with more cost, and the acquired operation lost more than four dollars for every dollar of revenue it brought. Then came the untangling.
20:03
Unidentified speaker (speaker_0): Recursion sold Essentia's Austrian operations in 2025, booking a loss on the disposal of the Acsentia GMBH business and a fee to terminate the Vienna lease. Facilities were consolidated, systems merged, and teams trimmed, first in the weeks after the deal closed and then in the broader 2025
20:22
Unidentified speaker (speaker_0): restructuring. Reasonable people can read that sequence two ways.
20:26
Unidentified speaker (UNKNOWN): It
20:27
Unidentified speaker (speaker_0): can be disciplined integration, quickly removing duplication.
20:31
Unidentified speaker (UNKNOWN): It
20:31
Unidentified speaker (speaker_0): can also be evidence that part of what Recursion bought did not fit the strategy it was paying
20:36
Unidentified speaker (UNKNOWN): for. The
20:37
Unidentified speaker (speaker_0): most uncomfortable inheritance did not show up in the pipeline at all.
20:41
Unidentified speaker (UNKNOWN): When
20:41
Unidentified speaker (speaker_0): Recursion's auditor examined internal controls at the end of 2025, it concluded that they were not effective because of material weaknesses tied to the acquired extension. Acsentia business, including its financial close process and information technology controls.
20:56
Unidentified speaker (UNKNOWN): The
20:57
Unidentified speaker (speaker_0): financial statements themselves received a clean opinion, so this was not a finding that the numbers were wrong. It was a finding that the processes meant to catch errors were not yet reliable.
21:07
Unidentified speaker (UNKNOWN): For
21:08
Unidentified speaker (speaker_0): a company asking investors to trust its estimates, including the cost to complete estimates that drive its revenue recognition, that is not a footnote.
21:16
Unidentified speaker (UNKNOWN): The
21:17
Unidentified speaker (speaker_0): Acentia scorecard is therefore unresolved rather than failed. Recursion acquired capabilities that plausibly complement its own, programs including Rec six hundred seventeen that now sit in its clinical pipeline, and a second large pharma relationship.
21:31
Unidentified speaker (UNKNOWN): It
21:32
Unidentified speaker (speaker_0): also acquired operating losses, integration work and control weaknesses, and it paid with roughly a quarter of its own company.
21:54
Unidentified speaker (UNKNOWN): In
21:54
Unidentified speaker (speaker_0): the spring of twenty twenty five, recursion did something that companies built on the promise of abundance rarely enjoy doing. It said no to its own ideas.
22:03
Unidentified speaker (speaker_0): Alongside its first quarter results, the company announced it would stop or seek partners for three clinical programs: Rec 994 for a vascular brain malformation called cerebrocavernous malformation, rec 2282 for a tumor syndrome called neurofibromatosis type 2, and rec 3964 for recurrent infection with the gut
22:23
Unidentified speaker (speaker_0): bacterium C. diffusile. diffusel.
22:25
Unidentified speaker (UNKNOWN): Weeks
22:26
Unidentified speaker (speaker_0): later, it cut roughly twenty percent of its personnel.
22:29
Unidentified speaker (UNKNOWN): The
22:29
Unidentified speaker (speaker_0): people who had built the most aggressive version of the recursion pipeline were now being asked to run a smaller
22:35
Unidentified speaker (UNKNOWN): one.
22:36
Unidentified speaker (speaker_0): To see why, look at what the merged company had become. Research and development spending climbed from about two hundred forty-one million dollars in twenty twenty-three to about four $475 hundred seventy-five million dollars in twenty 2025, twenty-five, nearly doubling in two years.
22:51
Unidentified speaker (UNKNOWN): The
22:51
Unidentified speaker (speaker_0): jump had three engines. The first was the acquired Exentia organization, with its own chemists, facilities, and programs. The second was data. Recursion had agreed to buy large volumes of de-identified patient records and molecular data from the precision medicine company Tempus, and those purchases cost about $49.9
23:11
Unidentified speaker (speaker_0): million in 2025 alone.
23:13
Unidentified speaker (UNKNOWN): The
23:14
Unidentified speaker (speaker_0): third was acquired in-process RD, the accounting cost of buying programs before they are proven. Add general and administrative costs and recursions operating costs rose to around $723 million in 2025 against revenue of $74 million. RD alone was more than six
23:34
Unidentified speaker (speaker_0): times revenue. No partner model, however generous, was going to close that gap.
23:39
Unidentified speaker (UNKNOWN): The
23:39
Unidentified speaker (speaker_0): TEMPUS spending deserves a moment because it shows how the platform's appetite had changed. Recursion's original engine generated its own data from cells in its own lab. The TEPUS arrangement added a different raw material, real world clinical and genomic records from cancer patients, meant to help connect cellular patterns to human disease and to
23:59
Unidentified speaker (speaker_0): choose which patients a drug might help. Recursion paid part of partly in shares, so the data cost shareholders twice, once in cash and once in dilution.
24:09
Unidentified speaker (UNKNOWN): When the
24:10
Unidentified speaker (speaker_0): budget tightened, spending on those purchases was among the first things to slow, falling by about forty-seven million dollars in the first half of 2026 compared with a year earlier. That is a sensible cut, if the data had become less essential, and a quiet admission that not
24:26
Unidentified speaker (UNKNOWN): a lot of the same.
24:27
Unidentified speaker (speaker_0): every input to the machine was earning its keep.
24:30
Unidentified speaker (UNKNOWN): It
24:30
Unidentified speaker (speaker_0): would be easy to tell the 2025 cuts as a tidy efficiency story, in which a sharper management team trimmed fat.
24:38
Unidentified speaker (UNKNOWN): The
24:38
Unidentified speaker (speaker_0): record is messier. Recursion grew its headcount rapidly, including through acquisition, and then reversed part of that growth. It had already trimmed staff in the weeks after the Acentia Excentia deal closed.
24:49
Unidentified speaker (UNKNOWN): The
24:49
Unidentified speaker (speaker_0): workforce reduction
24:50
Unidentified speaker (UNKNOWN): was a very good thing.
24:51
Unidentified speaker (speaker_0): correction to an expansion, not an independent act of discipline. That does not make it wrong. It means the cuts should be judged by what they preserved, not by how large they were.
25:01
Unidentified speaker (UNKNOWN): The
25:02
Unidentified speaker (speaker_0): portfolio choices tell the clearer story. Several of Recursion's earliest clinical programs had been built around existing molecules that the platform pointed toward new diseases, and the three it stepped back from were among the programs. it had once showcased. Management said it was concentrating capital on programs with stronger scientific rationale,
25:22
Unidentified speaker (speaker_0): nearer term data, or better commercial potential, and on its partnerships.
25:27
Unidentified speaker (UNKNOWN): An
25:27
Unidentified speaker (speaker_0): investor can respect that and still notice what it implies. A meaningful share of the first generation of platform-derived platform derived clinical bets did not survive as funded programs.
25:37
Unidentified speaker (UNKNOWN): The
25:37
Unidentified speaker (speaker_0): cost discipline that followed. is measurable. Recursion reported about $400 million of cash operating expenses in 2025, roughly 10% below what it had originally guided. It then set its 2026 target at under $390 million, and by the August call had lowered that to about $375 million.
25:56
Unidentified speaker (UNKNOWN): In
25:57
Unidentified speaker (speaker_0): the first half of 2026, RD expense fell about 31% from the prior year, driven by lower. platform spending, fewer tempest data purchases, and lower personnel costs, along with the pipeline reprioritization. Beating your own spending guidance and then cutting it again is the kind of behavior that builds credibility because it is the
26:16
Unidentified speaker (speaker_0): opposite of the familiar biotech pattern of guiding low and spending high.
26:21
Unidentified speaker (UNKNOWN): There
26:21
Unidentified speaker (speaker_0): is a vocabulary trap here worth flagging. Cash operating expense is a management measure. that excludes items such as stock-based compensation and some other costs. It is a useful gauge of how fast money leaves the building, but it is not gap operating loss, and it is not the same as cash flow from operations, which also moves with partner payments and working
26:41
Unidentified speaker (speaker_0): capital. Even at $375 million a year, against revenue that ran about $53 million over the trailing twelve months, recursion is nowhere near break-even. Lower spending extends the runway. It does not change the destination.
26:55
Unidentified speaker (UNKNOWN): So,
26:55
Unidentified speaker (speaker_0): what did management offer as evidence that a smaller budget preserved the engine?
27:00
Unidentified speaker (UNKNOWN): On
27:00
Unidentified speaker (speaker_0): the Q4 2025 call, Kahn framed the industry as moving from building models and announcing collaborations to showing measurable impact in drug programs, and she presented recursion's plan in those terms: fewer programs, each with clearer data milestones.
27:14
Unidentified speaker (UNKNOWN): By
27:15
Unidentified speaker (speaker_0): the Q two twenty twenty six call, the evidence she could point to was the Genentech target advancing and the Rec four hundred eighty one data. That is real, but it is two data points across a period of heavy reorganization. The harder tests, whether partner milestones and clinical progress continue at the same or better pace per dollar spent, needs
27:34
Unidentified speaker (speaker_0): more quarters to resolve.
27:37
Unidentified speaker (UNKNOWN): The
27:37
Unidentified speaker (speaker_0): calibrated reading of this chapter is a very that the spending reduction was genuine reprioritization rather than accounting cosmetics. Programs ended, people left, and expensive data purchases slowed. Management has shown it can reset costs and hit its targets. What it has not shown is that the platform's productive
27:56
Unidentified speaker (speaker_0): capacity survived intact, because that capacity is measured in milestones and patient data that arrive with. long lags.
28:04
Unidentified speaker (UNKNOWN): A
28:04
Unidentified speaker (speaker_0): smaller budget is only a victory if the programs left standing produce evidence that could not have been bought more cheaply elsewhere.
28:11
Unidentified speaker (UNKNOWN): Of
28:12
Unidentified speaker (speaker_0): all those surviving programs, one has carried more of the story's weight than any other. For a person with familial adnomatous polyposis, the colon is a field that keeps growing weeds.
28:24
Unidentified speaker (UNKNOWN): The
28:24
Unidentified speaker (speaker_0): disease is inherited, usually through a mutation. in a gene called APC, and it causes hundreds or even thousands of polyps to form in the large intestine, often beginning in adolescence. Left alone, those polyps almost inevitably turn cancerous.
28:40
Unidentified speaker (UNKNOWN): The
28:40
Unidentified speaker (speaker_0): standard answer is surgery, frequently removal of the colon in early adulthood, followed by a lifetime of endoscopies to monitor and cut away polyps that keep appearing in the remaining bowel. and upper intestine.
29:01
Unidentified speaker (speaker_0): Recursion estimates that more than fifty thousand diagnosed patients live with FAP across the United States and the five largest European markets. That is a rare disease population, small enough to qualify for regulatory incentives and large enough to support a commercial medicine if one works.
29:18
Unidentified speaker (UNKNOWN): It
29:18
Unidentified speaker (speaker_0): is also a population where a pill that shrinks polyps would mean something tangible. Fewer procedures, perhaps delayed surgery, perhaps less cancer risk, though that last benefit would take years to demonstrate.
29:31
Unidentified speaker (UNKNOWN): The
29:31
Unidentified speaker (speaker_0): trail from platform to patient is worth tracing carefully because it shows exactly what the platform did and did not do. Recursion's image-based experiments modeled the cellular consequences of losing APC function and searched for compounds that pushed those diseased cells back toward a healthy appearance. One class that stood out was
29:51
Unidentified speaker (speaker_0): inhibitors of MEC, an enzyme and a growth signaling pathway that cancer researchers have targeted for years. REC 4881 is a MEC 1-2 inhibitor that Recursion licensed from Takeda. rather than one it invented from scratch.
30:05
Unidentified speaker (UNKNOWN): In
30:05
Unidentified speaker (speaker_0): other words, the platform's contribution was the hypothesis, this kind of drug in this disease. Clinical testing is what turns a hypothesis into evidence.
30:16
Unidentified speaker (UNKNOWN): The
30:16
Unidentified speaker (speaker_0): Tupelo study supplied the first such evidence. Patients with FAP received RAC 4881, and management reported a median 43% reduction in polyp burden. after about three months of treatment. That is a striking number in a disease with nothing approved to compare it with.
30:45
Unidentified speaker (speaker_0): Matters to patients, which is avoiding cancer and surgery. MEC inhibitors as a class carry known side effects, including skin rash and gastrointestinal problems, so tolerability over months and years is as important as the size of the response.
31:01
Unidentified speaker (UNKNOWN): On
31:01
Unidentified speaker (speaker_0): the August call, Conn named the next Gates.
31:04
Unidentified speaker (UNKNOWN): The
31:04
Unidentified speaker (speaker_0): company was continuing enrollment and working on dose optimization, the process of finding the dose that keeps most of the benefit with fewer side effects. It planned further clinical data. and it intended to discuss with the FDA what a potential registration path would look like, which in a disease without an approved drug may require agreeing on
31:24
Unidentified speaker (speaker_0): endpoints that regulators will accept. Each of those steps can go wrong, and each will take time, measured in quarters, not weeks.
31:33
Unidentified speaker (UNKNOWN): The
31:33
Unidentified speaker (speaker_0): positive result needs to sit beside the pipeline record, because the honest question is not whether recursion could
31:38
Unidentified speaker (UNKNOWN): be a good idea.
31:39
Unidentified speaker (speaker_0): can produce one encouraging signal, but at what rate its platform-derived programs convert.
31:44
Unidentified speaker (UNKNOWN): The
31:44
Unidentified speaker (speaker_0): three programs Recursion discontinued or put up for partnering in 2025 had all reached the clinic. Before Rec 4881's data, Recursion's clinical record was mostly a story of programs that did not make the cut.
31:58
Unidentified speaker (UNKNOWN): The
31:58
Unidentified speaker (speaker_0): FAP result narrows the claim that the platform produces medicines to a smaller but now defensible version. The platform has produced at least one hypothesis that looks promising in patients.
32:10
Unidentified speaker (UNKNOWN): The
32:10
Unidentified speaker (speaker_0): rest of the clinical pipeline should be treated as options rather than assets. REC six one seven, a CDK seven inhibitor for advanced solid tumors that came from Excentia, Acentia, has reported early data,
32:23
Unidentified speaker (UNKNOWN): and
32:23
Unidentified speaker (speaker_0): the company lists several other oncology and rare diseases. disease programs at clinical or near clinical stages. Each could matter. None should be counted as revenue, because in oncology, especially, early stage signals often fail to show the differentiation needed to win in larger trials.
32:42
Unidentified speaker (UNKNOWN): A
32:42
Unidentified speaker (speaker_0): pipeline count is a measure of how many lottery tickets you hold, not of how many will pay
32:47
Unidentified speaker (UNKNOWN): out.
32:48
Unidentified speaker (speaker_0): Recursion also argues that its chemistry is getting. more efficient, that with Acentia's design tools it can reach a development candidate by synthesizing fewer compounds and running faster design cycles than industry norms.
33:00
Unidentified speaker (UNKNOWN): That
33:00
Unidentified speaker (speaker_0): claim may well be true, and it would be valuable,
33:03
Unidentified speaker (UNKNOWN): but
33:03
Unidentified speaker (speaker_0): it measures a step on the way to a medicine, not the medicine itself.
33:08
Unidentified speaker (UNKNOWN): A
33:08
Unidentified speaker (speaker_0): faster route to a molecule that fails in phase two saves money only in the narrowest sense. The end point that matters for this company is medicines that work in people and can be developed at a cost that leaves something for shareholders after RD. Consider what this one program has to carry. Recursion's RD spending dwarfed
33:28
Unidentified speaker (speaker_0): its revenue in 2025. If REC four eight eight one succeeds, it validates a hypothesis the platform generated and provides the company's first realistic path to product revenue.
33:39
Unidentified speaker (speaker_0): It does not by itself prove that the platform's economics work, because one success out of a long list of attempts is what conventional biotech also produces. One clinical signal can change the story. Several independent outcomes from programs with different biology must arrive before it changes the confidence.
33:59
Unidentified speaker (UNKNOWN): And
33:59
Unidentified speaker (speaker_0): that raises the competitive question in full.
34:01
Unidentified speaker (UNKNOWN): If
34:01
Unidentified speaker (speaker_0): success depends on repeatable outcomes, what exactly does recursion have that others cannot assemble? On the fourth quarter 2025 call, Kahn described a turning point, not just for recursion, but for the whole field.
34:21
Unidentified speaker (speaker_0): collaborations. The next phase would be judged on measurable impact in actual drug programs.
34:27
Unidentified speaker (UNKNOWN): It
34:27
Unidentified speaker (speaker_0): was a candid framing because it set the bar where skeptics had long wanted
34:31
Unidentified speaker (UNKNOWN): it.
34:31
Unidentified speaker (speaker_0): Under that standard, the question is no longer who has the most impressive technology, it is who can turn technology into clinical outcomes repeatedly and get paid for
34:41
Unidentified speaker (UNKNOWN): it.
34:42
Unidentified speaker (speaker_0): Start with the industry's structure. Drug discovery is long, expensive and failure prone. Large pharmaceutical companies hold most of the money, but own the late-stage development and commercial machinery, and choose between building capabilities internally and contracting specialists. Into that structure have poured dozens of companies claiming AI
35:02
Unidentified speaker (speaker_0): advantages, from software vendors to venture-backed discovery shops. And the cost of generating a plausible hypothesis keeps falling as open source protein structure and molecule generation models spread. When generating ideas gets cheaper, the scarce resources move downstream. High quality experimental data, the ability
35:22
Unidentified speaker (speaker_0): to make and test molecules, and above all, clinical success. Recursion sits among very different kinds of competitor,
35:30
Unidentified speaker (UNKNOWN): and
35:30
Unidentified speaker (speaker_0): comparisons need care because their business models are not alike. Schrdinger sells physics-based simulation software to drug developers while also running. its own programs, so it has a recurring software revenue stream Recursion lacks. Insilico Medicine has built a pipeline of AI designed molecules and is often cited as an AI
35:49
Unidentified speaker (speaker_0): native peer, but its scale and disclosure differ, and no reliable market share figures exist for this field. Big pharma's own data science groups are perhaps the most important competitors, because they are also recursion's customers. There is no industry body that publishes market shares for AI enabled discovery, and
36:09
Unidentified speaker (speaker_0): Recursion does not claim one. Run the competitive forces through that structure and the picture is sobering. Buyers are few and powerful, two customers represented substantially all of Recursion's twenty 2025 twenty five revenue, which means each negotiation is with a counterparty that has alternative. alternatives and leverage.
36:28
Unidentified speaker (speaker_0): Switching costs are not evident in the filings, which disclose no minimum recurring commitments.
36:34
Unidentified speaker (UNKNOWN): The
36:34
Unidentified speaker (speaker_0): threat of substitutes is high because a partner can license a model elsewhere, build its own, or simply run conventional screening.
36:42
Unidentified speaker (UNKNOWN): New
36:43
Unidentified speaker (speaker_0): entrants keep arriving with fresh capital.
36:45
Unidentified speaker (UNKNOWN): The
36:46
Unidentified speaker (speaker_0): supplier side matters less, though recursion relies on a small number of vendors for
36:50
Unidentified speaker (UNKNOWN): the
36:51
Unidentified speaker (speaker_0): certain research and clinical work and made large data purchases from Tempest.
36:55
Unidentified speaker (UNKNOWN): The
36:56
Unidentified speaker (speaker_0): forces that favor recursion are the ones that are hardest to buy. Years of controlled proprietary experimental data, the wet lab capacity to produce more, and an organization that connects it to chemistry Industry and clinical development. Hamilton Helmer's framework for durable advantage, which he calls the seven. powers,
37:15
Unidentified speaker (speaker_0): sharpens the test. Scale economies would show up as falling cost per useful experiment or per program. Recursion's spending history does not yet show that. Network effects do not apply in any meaningful sense. Switching costs are not demonstrated as partners are not locked in. Brand matters a little in recruiting and partnering, not in
37:35
Unidentified speaker (speaker_0): pricing. Counterpositioning is the most interesting candidate. Incumbents built around traditional hypothesis first research may find it awkward to reorganize around industrial scale data generation, though many are trying. A cornered resource, meaning the proprietary data set and the lab that produces it, is the core claim, and it is real as an
37:55
Unidentified speaker (speaker_0): asset, but unproven as a source of superior returns. Process power, the hard to copy habits of running an integrated lab to clinical. clinic loop is what Khan's integration answer actually describes, and it is the power the next few years will either confirm or refute.
38:10
Unidentified speaker (UNKNOWN): The
38:10
Unidentified speaker (speaker_0): affirmative evidence is not nothing. Roche and Genentech have accepted several neuroscience and other maps and pushed a target into discovery. Sonofi has paid milestones, and Rec four eight eight one has produced a patient patient-level level signal. Cumulative partner cash of more than five $500 hundred million dollars shows the that sophisticated buyers have paid for the work. Each of those is an
38:30
Unidentified speaker (speaker_0): independent check on the platform from someone who did not have to say yes. Technology disruption cuts both ways for a company like this. The same wave of machine learning tools that made recursion story fashionable is now lowering the cost for everyone else. A pharma team can download capable open models, rent computing power by the hour, and buy datasets from vendors.
38:50
Unidentified speaker (speaker_0): which erodes any advantage that rested on software alone.
38:54
Unidentified speaker (UNKNOWN): What
38:54
Unidentified speaker (speaker_0): it cannot easily download is a decade of carefully controlled experiments, run the same way with the same cell lines, or the institutional habit of turning those experiments into chemistry and clinical decisions.
39:07
Unidentified speaker (UNKNOWN): That is
39:07
Unidentified speaker (speaker_0): why Khan's answer emphasized Emphasize the integrated workflow.
39:11
Unidentified speaker (UNKNOWN): It
39:11
Unidentified speaker (speaker_0): is also why the claim must be proven in outcomes. If the integrated workflow is truly superior, the evidence will be programs, not press releases.
39:33
Unidentified speaker (speaker_0): The industry norm. RD runs at several times revenue, and the market, at about 42.5 times trailing sales, is clearly paying for something beyond the current business, which is reasonable for a pre-commercial biotech, but means the price embeds an expectation of future success rather than a record of
39:51
Unidentified speaker (UNKNOWN): it. There
39:52
Unidentified speaker (speaker_0): is no consistent history of recursion zone multiple or a clean set of same-date peer Eight multiples that would show whether that expectation is high or low by the standards of its class.
40:02
Unidentified speaker (UNKNOWN): The
40:03
Unidentified speaker (speaker_0): verdict on the moat is therefore a version of intact but unproven.
40:08
Unidentified speaker (UNKNOWN): The
40:08
Unidentified speaker (speaker_0): most credible edge is the combination of proprietary experimental data with biology, chemistry, and clinical workflows in one organization, checked by partners who pay. Evidence of pricing power, lock-in, or a repeatable cost advantage remains thin. Three measures would confirm or falsify it. Partner programs that advance
40:28
Unidentified speaker (speaker_0): into paid milestones rather than stalling after map acceptance, clinical outcomes per dollar of R and D, and cash burn against runway. The person now responsible for moving all three, however, arrived only recently in the chief executive's chair. On january first, twenty twenty six, Najat Khan became chief executive of a company she had not
40:48
Unidentified speaker (speaker_0): founded and had joined only a couple of years earlier. Chris Gibson, who had led Recursion since its days as a university spin out, moved to chair the board.
40:57
Unidentified speaker (UNKNOWN): The
40:57
Unidentified speaker (speaker_0): handoff came at an awkward moment, and an honest one. The Excentia deal was a year old, the restructuring was fresh, and the company's own description of its next phase was about proof rather than promise. Khan Conn was inheriting not a startup to grow, but a combined organization to make accountable. Conn arrived with a profile
41:17
Unidentified speaker (speaker_0): built for that brief. Trained as a scientist, she had spent years in strategy and data science roles in big pharma, most recently at Johnson
41:25
Unidentified speaker (UNKNOWN): ⁇
41:25
Unidentified speaker (speaker_0): Johnson's pharmaceutical business, where she led data science before joining Recursion as its chief research and development officer and chief commercial officer, and later president. That background matters in two directions. She knows how large pharmaceuticals pharmaceutical are. companies evaluate partners, which is useful when two of them account for nearly all your revenue. And she came to
41:44
Unidentified speaker (speaker_0): recursion from the buy side of AI drug discovery, which may explain her emphasis on measurable program impact over technology narratives.
41:57
Unidentified speaker (speaker_0): joined recursion in November twenty twenty four after serving as Excentia's chief financial officer and chief strategy officer. That puts the integration of the acquired business, its operating losses, and the remediation of its control weaknesses squarely within the remit of the executive who knew that business best. It is a sensible appointment for continuity, and it is also
42:17
Unidentified speaker (speaker_0): the point where accountability concentrates. If Excentia's financial close and IT controls are not fixed, the person responsible was there on both sides of the deal. Compensation is mostly equity, which in principle aligns executives with shareholders, but also makes pay a large source of dilution.
42:33
Unidentified speaker (UNKNOWN): In
42:34
Unidentified speaker (speaker_0): 2025, Gibson received about $9.6 million in reported compensation, the bulk in stock and option awards, roughly the same as in each of the two prior years, even as annual net losses grew from about $328 million to about $645 million.
42:51
Unidentified speaker (speaker_0): Khan received about $5.35 million, plus an additional $1 million in intended value equity awards tied to her transition to chief executive. Executives received 80% of their target annual bonuses for 2025.
43:05
Unidentified speaker (UNKNOWN): Those
43:06
Unidentified speaker (speaker_0): numbers are not unusual for a NASDAQ biotech of this size, but they invite a simple question: are the incentives tied to milestones, cost guidance? and dilution, the measures that matter here, or to activity?
43:19
Unidentified speaker (UNKNOWN): The
43:19
Unidentified speaker (speaker_0): eighty percent payout suggests the board judged twenty twenty five as partly successful, which roughly matches the evidence. Founder influence persists without control. Gibson and his affiliates hold all of Recursion's Class B shares, which carry ten votes each. At the end of 2025, that block represented about 9.6% of the
43:38
Unidentified speaker (UNKNOWN): City.
43:39
Unidentified speaker (speaker_0): voting power, potentially rising to about 10.8% if specified awards vested or were exercised. That is meaningful sway in a close vote, not a controlling stake, and the Class B shares are scheduled to convert automatically under specified conditions, including in April 2028.
43:56
Unidentified speaker (UNKNOWN): The
43:57
Unidentified speaker (speaker_0): largest economic holders, as of April 2026, twenty twenty six were index and active managers, Vanguard, with about nine point zero percent of the Class A shares, BlackRock with about seven point two percent, and Kathy Woods ARC with about seven point one percent. ARC's presence is a reminder that part of recursion's shareholder base bought into the long duration
44:16
Unidentified speaker (speaker_0): AI thesis, and such holders tend to be sensitive to whether that thesis is advancing. How has the team behaved as distinct from what it has said?
44:25
Unidentified speaker (UNKNOWN): The
44:25
Unidentified speaker (speaker_0): measurable record is mostly. favorable on cost. 2025 cash spending came in about ten percent under the original target, and twenty twenty six guidance has been lowered twice. Programs were cut when data did not support them, and facilities and systems were consolidated. Those are course corrections with consequences, the opposite of
44:45
Unidentified speaker (speaker_0): drift.
44:46
Unidentified speaker (UNKNOWN): The
44:46
Unidentified speaker (speaker_0): control finding belongs in the same frame. Investors received financial advanced. statements with an unqualified audit opinion, but internal controls were judged ineffective because excentia-related weaknesses were still unremediated at year end 2025. Management reported remediation work underway. Until the auditor confirms that the fixes have
45:06
Unidentified speaker (speaker_0): operated effectively for a sufficient period, that remains a live credibility test, especially for a company whose revenue relies on cost estimates. Shareholders, for their part, have not revolted. At the june twenty twenty six annual meeting, the Sayon Pay proposal passed with about two hundred six million votes for and about thirty-one million against,
45:26
Unidentified speaker (speaker_0): a clear majority, though lower than the roughly ninety-eight percent support the previous year. That shift is a mild signal, not a rebellion, and votes are no substitute for operating results.
45:37
Unidentified speaker (UNKNOWN): Reading
45:38
Unidentified speaker (speaker_0): the two most recent calls together, the pattern is consistent. Management quantifies cost targets and runway precisely and is more general when asked about timelines for partner milestones and the size of its competitive advantage.
45:51
Unidentified speaker (UNKNOWN): The
45:51
Unidentified speaker (speaker_0): differentiation answer, integration, rather than AI as such, did not change between the two calls, which is to its credit.
45:59
Unidentified speaker (UNKNOWN): The
45:59
Unidentified speaker (speaker_0): quantities that will judge it, however, are the ones that come from the bank account.
46:09
Unidentified speaker (speaker_0): That balance, the company said, was enough to fund operations into early twenty twenty eight.
46:21
Unidentified speaker (speaker_0): Building in half a year, even with spending falling. Meanwhile, a fresh three hundred million dollar at the market stock program sat ready, untouched as of june thirty.
46:31
Unidentified speaker (UNKNOWN): The
46:31
Unidentified speaker (speaker_0): runway and the share issuance facility are two halves of the same plan. Start with the gap between accounting losses and cash. Over the seven years from twenty nineteen through twenty twenty five, recursion's cumulative net losses were about two point zero billion dollars, while cash burned in operations was about one point four billion dollars.
46:51
Unidentified speaker (UNKNOWN): The
46:51
Unidentified speaker (speaker_0): difference is mostly non-cash charges.
46:53
Unidentified speaker (UNKNOWN): In
46:53
Unidentified speaker (speaker_0): 2025 alone, the company added back about $111 million of stock-based compensation and about $84 million of depreciation and amortization, plus the acquired in-process RD and other items, to get from its net loss to its operating cash Cash flow. flow.
47:09
Unidentified speaker (UNKNOWN): That
47:10
Unidentified speaker (speaker_0): is why operating cash use of about $372 million in 2025 looks much smaller than the $645 million net loss.
47:18
Unidentified speaker (UNKNOWN): It
47:19
Unidentified speaker (speaker_0): does not make the business cash generative. Stock compensation is still a cost, it is simply paid in shares instead of dollars, which brings the cost back as dilution rather than as cash burn.
47:29
Unidentified speaker (UNKNOWN): Some
47:30
Unidentified speaker (speaker_0): of the 2025 cash picture was also flattered by timing. Operating cash flow benefited from about $50 million as prepaid data assets were used up. and about $33 million from other receivables and assets, partly offset by a $37 million drop in unearned revenue as earlier partner payments were worked off. Those swings will not repeat in
47:50
Unidentified speaker (speaker_0): the same direction forever. Unearned revenue in particular is cash that partners paid in advance. Once it is recognized, it no longer supports the runway.
47:58
Unidentified speaker (UNKNOWN): The
47:58
Unidentified speaker (speaker_0): balance sheet's liabilities are light by the standards that matter to lenders.
48:02
Unidentified speaker (UNKNOWN): At
48:02
Unidentified speaker (speaker_0): the end of 2025, Recursion reported only about $18.7 million of debt, consisting of notes for tenant improvements and financing for its supercomputer. It also had about $77.6 million of lease liabilities and about $147 million of purchase obligations, mostly research commitments. Those are real
48:22
Unidentified speaker (speaker_0): future claims on cash, but there is no covenant to breach, and no bond. maturity to refinance. Recursion's credit problem is not a lender. It is a business that spends far more than it earns, which can only be closed by partner payments, product revenue, or new equity.
48:39
Unidentified speaker (UNKNOWN): The
48:39
Unidentified speaker (speaker_0): record says which of those has done the work. Recursion's history is a long sequence of share sales. After the 2021 IPO came private placements in October 2022 and July 2022. 2023, a June 2024 public offering of about $35.4 million shares at $6.50 for roughly $216
48:59
Unidentified speaker (speaker_0): million net, and a Jeffries at the Market program that raised about $199 million between 2023 and early 2025. Then came the largest of all. In 2025, a city-run at-the-market at the market program raised about $492 million.
49:15
Unidentified speaker (speaker_0): net by selling about 99.9 million shares, using the facility in full. Add roughly 102 million shares issued for Accenture, shares issued to Tempest as payment for data licensing, and steady stock compensation, and the share base has expanded many times over since the IPO. Cash from financing activities totaled more than
49:35
Unidentified speaker (speaker_0): $1.9 one point nine billion dollars over the seven years.
49:38
Unidentified speaker (UNKNOWN): The per
49:39
Unidentified speaker (speaker_0): share arithmetic shows who bears that cost. Recursion's total net loss grew from about three hundred twenty eight million dollars in twenty twenty three to about six hundred forty five million dollars in twenty twenty five, nearly doubling. Yet its loss per share shrank over the same period from about a dollar forty one to about a dollar twenty two, then to about ninety-eight
49:58
Unidentified speaker (speaker_0): cents over the twelve months to june twenty 2026. twenty six.
50:01
Unidentified speaker (UNKNOWN): The only
50:01
Unidentified speaker (speaker_0): way a bigger loss. becomes a smaller loss per share is a much larger number of shares.
50:07
Unidentified speaker (UNKNOWN): A
50:07
Unidentified speaker (speaker_0): headline that says losses per share are improving is, in this case, mostly a description of dilution. Shareholders did not lose less. They each owned a smaller piece of a larger loss. An at the market program, for listeners unfamiliar with it, is a way for a company to dribble shares into the market through a broker. at
50:27
Unidentified speaker (speaker_0): prevailing prices rather than in one large offering. It is flexible and cheaper than a traditional deal, and it lets management sell when the price is strong.
50:37
Unidentified speaker (UNKNOWN): It
50:38
Unidentified speaker (speaker_0): also makes dilution continuous and quiet.
50:41
Unidentified speaker (UNKNOWN): In
50:41
Unidentified speaker (speaker_0): February 2026, Recursion established a new $300 million program with TD Cowan, and as of June 30, had sold no shares on. under it.
50:56
Unidentified speaker (speaker_0): The facility's existence is also a statement about how the gap will eventually be closed if partners and products do not close it first. Partner payments are the wild card in the runway math. Upfront fees and milestones can extend the clock, sometimes by months, but their timing depends on recursion delivering work. partners accepting it,
51:16
Unidentified speaker (speaker_0): and programs advancing. Management's runway estimate rests on assumptions about those receipts and about spending that investors cannot fully check from the outside. Treat into early 2028 as an estimate built on management's plan, not a guaranteed date, and watch each quarter's cash use against it.
51:36
Unidentified speaker (UNKNOWN): A
51:36
Unidentified speaker (speaker_0): skeptical investor would push on one more point. If this is a disciplined platform, what fixed evidence decides which programs and technology investments stop receiving capital? Management has cut programs once, decisively. It has not published the decision rules, such as the data thresholds that would trigger a stop or the cost per
51:56
Unidentified speaker (speaker_0): program ceiling that would let outsiders hold it to account before the next cut becomes necessary.
52:01
Unidentified speaker (UNKNOWN): With a
52:02
Unidentified speaker (speaker_0): free cash flow yield of about negative 16% at the October share price, shareholders are financing roughly a sixth of the company's market value in cash burn every year.
52:12
Unidentified speaker (UNKNOWN): The
52:13
Unidentified speaker (speaker_0): runway may reach early twenty twenty eight. The more important question is what proof recursion can buy before then and what the market will make of it. Put two documents side by side and the debate writes itself.
52:26
Unidentified speaker (UNKNOWN): One is
52:26
Unidentified speaker (speaker_0): the second quarter twenty twenty six report. Operating costs lower, cash guidance cut again, a genentec target advancing, and REC four eight eight one data that gave patients with FAP a reason for hope. The other is the share price on october twenty ninth, twenty twenty six, about four dollars thirty-four cents,
52:46
Unidentified speaker (speaker_0): roughly a quarter below its fifty-two-week fifty-two week high of five eighty seven, and well above its lower. low of two hundred eighty-four, valuing the company at about two point three billion dollars. That price sat against about fifty-three million dollars of trailing revenue, five hundred fifty-seven million dollars of June cash, and a negative fifteen point seven percent free cash flow yield.
53:06
Unidentified speaker (UNKNOWN): The
53:06
Unidentified speaker (speaker_0): stock had fallen as much as eighty six percent from its peak at some point during the previous five years, and it moves with a volatility above seventy 70% percent a year. Investors have treated it as a referendum on whether AI can make drugs, and the referendum is still being counted.
53:21
Unidentified speaker (UNKNOWN): It
53:22
Unidentified speaker (speaker_0): helps to ask what that price assumes. Take away the cash and the enterprise value was about $1.8 billion, roughly 34 times trailing revenue. That is the sum the market assigns to everything that is not money in the bank. The platform, the partnerships, REC four 4881, eight eight one, and the rest of the pipeline.
53:40
Unidentified speaker (UNKNOWN): The
53:40
Unidentified speaker (speaker_0): current partnership revenue cannot justify it on any conventional multiple, so the price is implicitly a bet that at least one product reaches the market or that partner economics grow far larger than today. The book value per share of about $1.76 against a share price of about $4.34 tells a similar story. The market values the company at roughly two and a half
54:00
Unidentified speaker (speaker_0): times what shareholders have put in, net of loss. losses. There is no consistent history of these multiples or same-date peer figures that would show whether that premium is generous or modest for its class, so the multiple is best read as a statement of expectation rather than a verdict.
54:15
Unidentified speaker (UNKNOWN): The
54:15
Unidentified speaker (speaker_0): bull case begins with partners. Roche and Genentech have accepted multiple maps, paying fees each time, and one neuroscience target has moved into a joint discovery program. Sinofi has paid milestones. and cumulative partner cash has passed half a billion dollars. It continues in the clinic. REC four eight eight one has
54:35
Unidentified speaker (speaker_0): produced a meaningful early signal in a disease with no approved therapy, with a path toward regulatory discussions, and REC six one seven and other programs give the company several more shots.
54:47
Unidentified speaker (UNKNOWN): It
54:47
Unidentified speaker (speaker_0): adds a cost base that is shrinking without, so far, visibly slowing the programs that matter, which extends runway and reduces how often shareholders must be asked for money. And it points to a market that might reward a credible AI-to-clinic platform with a scarcity value, because few companies have both a large
55:07
Unidentified speaker (speaker_0): proprietary experimental data set and clinical programs to show for it.
55:11
Unidentified speaker (UNKNOWN): The
55:12
Unidentified speaker (speaker_0): Bear case is assembled from the same record. Three clinical programs that once anchored the pipeline were discontinued or put up for partnering in 2025. Losses remain enormous and cash use substantial. Even after the cuts, the company spends several times its revenue every year. Revenue depends on two customers and fell
55:32
Unidentified speaker (speaker_0): about sixty percent in the first half of twenty 2026. twenty six.
55:35
Unidentified speaker (UNKNOWN): The
55:35
Unidentified speaker (speaker_0): share count has grown dramatically through offerings at the at-the-market market. programs, and acquisition and stock compensation, and a new $300 million facility stands ready. And the defining clinical asset, REC four eight eight one, is an unlicensed molecule whose evidence so far comes from a small, uncontrolled study. Test
55:55
Unidentified speaker (speaker_0): the moat once more. Not by rerunning the forces, but by asking what would break it.
56:00
Unidentified speaker (UNKNOWN): The
56:00
Unidentified speaker (speaker_0): most credible edge, proprietary experimental data combined with integrated chemistry and clinical development, would be broken by substitution.
56:09
Unidentified speaker (UNKNOWN): If
56:09
Unidentified speaker (speaker_0): partners can get comparable insight from their own models, cheaper data, or other vendors, map fees would shrink and acceptance would slow. The best evidence against substitution so far is that Roche kept accepting maps and moved a target forward.
56:24
Unidentified speaker (UNKNOWN): The
56:25
Unidentified speaker (speaker_0): best evidence for it is that no one
56:26
Unidentified speaker (UNKNOWN): was a very good idea.
56:27
Unidentified speaker (speaker_0): long-term minimum commitments or switching costs appear in the filings, and that revenue fell sharply in 2026.
56:33
Unidentified speaker (UNKNOWN): The
56:34
Unidentified speaker (speaker_0): verdict?
56:34
Unidentified speaker (UNKNOWN): The
56:35
Unidentified speaker (speaker_0): mode is narrowed to a research supplier advantage with a few paying customers, intact but unproven as a source of durable economics. Test the acquisition through the fate of the capital. Recursion issued roughly a quarter of the combined company for Accenture, absorbed about one hundred and fifty eight million dollars of operating loss from it in twenty twenty five,
56:55
Unidentified speaker (speaker_0): sold part of its footprint at a loss and inherited control weaknesses. In return, it got chemistry capability, the Sinofi relationship, and programs including Rec six hundred seventeen.
57:05
Unidentified speaker (UNKNOWN): The
57:06
Unidentified speaker (speaker_0): return on that capital is not yet visible, which is normal for a two-year-old biotech merger, and also a reason not to call it a success. Test management through the promises against outcomes. Beating 2025 cash spending guidance by about 10% and lowering 2026 guidance twice is real evidence of cost control.
57:25
Unidentified speaker (speaker_0): Remediating the control weaknesses, delivering milestones on time, and showing productivity per dollar are the confirming evidence still missing.
57:33
Unidentified speaker (UNKNOWN): A
57:33
Unidentified speaker (speaker_0): management team that has been right on spending is more credible than one that is not.
57:37
Unidentified speaker (UNKNOWN): But the
57:38
Unidentified speaker (speaker_0): harder promises are the scientific ones, and those depend partly on biology, no team controls.
57:43
Unidentified speaker (UNKNOWN): What
57:44
Unidentified speaker (speaker_0): would a skeptical activist ask for? Probably a published capital allocation framework, with explicit criteria for stopping programs and technology bets.
57:53
Unidentified speaker (UNKNOWN): A
57:53
Unidentified speaker (speaker_0): narrower focus on the clinical assets and partnerships that generate external Internal validation, incentive pay tied more tightly to milestones and per share outcomes. and a clearer explanation of why the market should pay for the platform separately from the pipeline.
58:08
Unidentified speaker (UNKNOWN): None
58:08
Unidentified speaker (speaker_0): of those requests would be unreasonable. Several are partly addressed by what management already did in 2025. Three measures matter more than any others for following this company. The first is partner conversion. Whether accepted maps and programs at Roche, Genentec, Genentech, and Sanafi advance into paid milestones and later. stage development.
58:28
Unidentified speaker (UNKNOWN): The
58:28
Unidentified speaker (speaker_0): latest reading is positive but thin,
58:31
Unidentified speaker (UNKNOWN): with
58:31
Unidentified speaker (speaker_0): one Genentech neuroscience target moved into joint discovery and cumulative partner cash above $500 million. The second is clinical progress per dollar of RD, where RD fell about 31% in the first half of 2026, while REC 4881 moved toward dose optimization and regulatory discussions.
58:50
Unidentified speaker (UNKNOWN): The
58:51
Unidentified speaker (speaker_0): third is cash burn and share count against runway, with $577 million at June 2026, a $375 million cash spending target for the year, and a runway estimate into early 2028.
59:04
Unidentified speaker (UNKNOWN): The
59:04
Unidentified speaker (speaker_0): next decision points are already scheduled by the company's own plans. More REC 4881 data and the outcome of FDA discussions on a potential registration path,
59:13
Unidentified speaker (UNKNOWN): the
59:13
Unidentified speaker (speaker_0): progress of partner programs. and continued evidence that cost reductions have not slowed the programs that matter.
59:20
Unidentified speaker (UNKNOWN): On
59:20
Unidentified speaker (speaker_0): balance, the bull case has concrete footholds that did not exist two years ago, but the bear case remains substantial, because the platform's advantages have not yet been monetized at scale, and shareholders are still funding the gap.
59:32
Unidentified speaker (UNKNOWN): The
59:33
Unidentified speaker (speaker_0): thesis is unproven until repeatable clinical and partner economics appear.
59:37
Unidentified speaker (UNKNOWN): That
59:37
Unidentified speaker (speaker_0): leaves a set of lessons that apply well. beyond this one company. Go back to the image that started it all.
59:42
Unidentified speaker (UNKNOWN): A
59:43
Unidentified speaker (speaker_0): plate of human cells under a microscope, each well lit up in fluorescent color, each picture fed to a machine. Then follow the chain forward. A pattern in a dish becomes a hypothesis. The hypothesis becomes a map a partner accepts, or a molecule a chemist designs.
1:00:00
Unidentified speaker (UNKNOWN): The
1:00:01
Unidentified speaker (speaker_0): molecule enters a trial.
1:00:02
Unidentified speaker (UNKNOWN): The
1:00:03
Unidentified speaker (speaker_0): trial produces data.
1:00:04
Unidentified speaker (UNKNOWN): The
1:00:04
Unidentified speaker (speaker_0): data persuades a regulator. And somewhere along that chain, at every link, someone has to pay for the next step. Recursion's story is a lesson in how different each link is and how each needs its own evidence.
1:00:18
Unidentified speaker (UNKNOWN): The
1:00:19
Unidentified speaker (speaker_0): first lesson is about data. Recursion's proprietary biological data set was a genuine achievement, and it turned out to be the beginning of the argument rather than the end of it. Partners paid for what the data could tell them, not for the data itself, and the market has priced the company on what the data might eventually produce. The test remains whether it leads to
1:00:38
Unidentified speaker (speaker_0): decisions other teams cannot make as well.
1:00:41
Unidentified speaker (UNKNOWN): The
1:00:42
Unidentified speaker (speaker_0): second lesson is about acquisitions.
1:00:44
Unidentified speaker (UNKNOWN): The
1:00:44
Unidentified speaker (speaker_0): Accentia deal had an elegant logic, biology meeting chemistry, and that logic was persuasive enough to justify trying it.
1:00:51
Unidentified speaker (UNKNOWN): The
1:00:51
Unidentified speaker (speaker_0): acquired business's losses, the sale of part of it, and its control weaknesses all belong on the scorecard. Strategic fit earns a deal the right to be tested, not the right to be called a success. Investors who heard end-to-end platform should have asked for the scorecard that would prove
1:01:08
Unidentified speaker (UNKNOWN): it. The
1:01:08
Unidentified speaker (speaker_0): third lesson is about portfolios.
1:01:10
Unidentified speaker (UNKNOWN): When
1:01:11
Unidentified speaker (speaker_0): recursion stopped three early clinical programs, it admitted that some of its most visible early bets had not earned more capital.
1:01:18
Unidentified speaker (UNKNOWN): That
1:01:18
Unidentified speaker (speaker_0): admission is what made the Rec 4881 signal more believable because it showed the company would move money toward evidence and away from hope.
1:01:26
Unidentified speaker (UNKNOWN): A
1:01:27
Unidentified speaker (speaker_0): pipeline is worth something only when capital follows the data, even when the data says the old favorites should go.
1:01:33
Unidentified speaker (UNKNOWN): The
1:01:33
Unidentified speaker (speaker_0): fourth lesson is about time. Management says its runway extends into early 2028. Runway sounds like an asset, and in one sense it is, because it gives science time to work.
1:01:45
Unidentified speaker (UNKNOWN): But
1:01:45
Unidentified speaker (speaker_0): time in biotech is only valuable if each year buys proof that changes the next financing decision: a better price for new shares, a richer partner deal, or no need to raise at all.
1:01:57
Unidentified speaker (UNKNOWN): A
1:01:57
Unidentified speaker (speaker_0): runway that ends where it began, with the same questions unanswered, is just a slower runway. route to dilution.
1:02:04
Unidentified speaker (UNKNOWN): The
1:02:05
Unidentified speaker (speaker_0): fifth lesson is about what counts as proof.
1:02:08
Unidentified speaker (UNKNOWN): A
1:02:08
Unidentified speaker (speaker_0): model benchmark impresses engineers. A map acceptance impresses partners. REC four eight eight one's early patient signal impresses physicians. Only an approved medicine, prescribed and paid for, impresses all three and the bank account too.
1:02:24
Unidentified speaker (UNKNOWN): For
1:02:24
Unidentified speaker (speaker_0): AI drug discovery, the patient is the only judge that cannot be persuaded by a better pitch, which is why every other kind of evidence should be priced as a down payment on that final verdict, rather than a substitute for it. Tonight, Recursion is a company with more evidence than it has ever had, and less proof than its valuation implies.
1:02:44
Unidentified speaker (UNKNOWN): It
1:02:45
Unidentified speaker (speaker_0): enters this evidence building stage with a leaner organization, engaged partners, and its strongest clinical signal. yet. Its familiar constraints remain concentrated revenue, a shrinking cash balance, and available stock issuance. Each update either adds to the case or subtracts from
1:03:02
Unidentified speaker (UNKNOWN): it. The
1:03:03
Unidentified speaker (speaker_0): first moment to watch is REC four eight eight one. More patients, longer follow-up, Follow up and a settled dose will show whether the early polyp reductions hold, whether side effects are managed. manageable over many months, and whether the effect is large enough to matter.
1:03:33
Unidentified speaker (speaker_0): Past the current runway.
1:03:34
Unidentified speaker (UNKNOWN): The
1:03:34
Unidentified speaker (speaker_0): second is the partners. If programs at Roche, Genentec, and Sinofield. Sinofi advance from discovery toward development candidates and later stage milestones, the platform's claim to produce useful biology gets an external confirmation that money cannot buy.
1:03:49
Unidentified speaker (UNKNOWN): If
1:03:49
Unidentified speaker (speaker_0): map acceptances keep coming but the programs stall, the partnerships will look more like research services than a source of future royalties. Either way, it is worth keeping target acceptance separate from drug success because the industry's history is littered with validated targets that never became medicines.
1:04:07
Unidentified speaker (UNKNOWN): The
1:04:07
Unidentified speaker (speaker_0): third is the cash clock. Every quarter will show how much was spent and how many shares were outstanding, set against the company's estimate that the money will last into early 2028.
1:04:17
Unidentified speaker (UNKNOWN): A
1:04:18
Unidentified speaker (speaker_0): quarter with cash use above the pace implied by guidance or a burst of at-the-market at the market sales at low prices would shorten the story.
1:04:25
Unidentified speaker (UNKNOWN): A
1:04:25
Unidentified speaker (speaker_0): large partner payment? or a disciplined quarter would lengthen
1:04:29
Unidentified speaker (UNKNOWN): it. The
1:04:30
Unidentified speaker (speaker_0): fourth is quieter, but matters for trust. The auditor's verdict on whether the essentia-related control weaknesses have been fixed and have operated effectively. Clean controls will not move the share price on their own. Lingering weaknesses would undermine confidence in the estimates on which the company's revenue depends.
1:04:49
Unidentified speaker (UNKNOWN): What
1:04:49
Unidentified speaker (speaker_0): would change the company? conclusion? Repeatable patient level evidence from more than one program, partner economics that broaden beyond two customers and grow more durable, and lower cash burn per meaningful program advance. Any two of those would make recursion a meaningfully different company from its current position. None of
1:05:09
Unidentified speaker (speaker_0): them would by itself guarantee a medicine, because biology keeps the final vote.
1:05:14
Unidentified speaker (UNKNOWN): The tech
1:05:14
Unidentified speaker (speaker_0): tension that remains is simple to state and hard to resolve. Recursion has learned to read cells at an industrial scale, and now has to show it can do so faster than its money runs out. Think again of that plate of cells under the microscope in Salt Lake City, glowing in five or six colors, one image among millions.
1:05:35
Unidentified speaker (speaker_0): More than a decade and billions of dollars of shareholder money later. REC four eight eight one produced an early patient level signal, compressing the journey recursion has been promising into a single line of evidence.
1:05:48
Unidentified speaker (UNKNOWN): What
1:05:49
Unidentified speaker (speaker_0): makes this company distinctive is not the AI, which others have, or the losses which most biotechs share. It is the scale of the bet that biology can be made computable, and the bluntness of the test now in front of us.
1:06:03
Unidentified speaker (UNKNOWN): The
1:06:03
Unidentified speaker (speaker_0): cells are the input, the software is the method, the cash is the clock. The platform is the promise.
1:06:21
Unidentified speaker (speaker_0): Is for informational purposes only and should not be considered as investment advice. If you like our podcasts, please subscribe on Apple Podcasts, Spotify, or your favorite podcast player. And don't forget to follow us on X at MPOTop. Find thousands of stories of top companies on our website, mPor.top. mPor.top is brought to you by
1:06:41
Unidentified speaker (speaker_0): heyfin.co. Finn is a personalized junior AI research assistant for equity portfolio managers. Check it out at heyfin.co.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights